

**Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group.**

[Fountzilas G](#), [Athanasiadis A](#), [Kalogera-Fountzila A](#), [Aravantinos G](#), [Bafaloukos D](#), [Briasoulis E](#), [Dombros N](#), [Ioannidis I](#), [Pavlidis N](#), [Kosmidis P](#), [Skarlos D](#).

**Source**

First Department of Internal Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Macedonia, Greece.

**Abstract**

37 patients with advanced breast cancer resistant to anthracyclines were treated with paclitaxel 200 mg/m<sup>2</sup> by 3-h infusion and carboplatin at an area under the curve of 7 mg.min/ml every 4 weeks with G-CSF support. There were 5 (14%, 95% CI 3-25%) complete and 11 (30%, 95% CI 15-45%) partial responders. Median duration of response was 11.5 months (range 5.2-16.8+), median time to progression 8 months (range 0.26-16.8+) and median survival 12 months (range 0.5-19.6+). Grade 3-4 leucopenia (27%), thrombocytopenia (10%) and diarrhoea (5%) were noted. In conclusion, the combination of paclitaxel and carboplatin is active and well tolerated in patients with advanced breast cancer resistant to anthracyclines.